Deutsche Bank AG Invests $3.50 Million in IDEAYA Biosciences, Inc. $IDYA

Key Points

• Deutsche Bank initiated a $3.50 million position in IDEAYA Biosciences during the second quarter, purchasing 93,844 shares. Institutional investors collectively own 98.29% of the company.
• IDEAYA shares opened at $41.58, near their 12-month high of $42.68, while the company reported a quarterly loss of $1.22 per share—worse than analyst expectations—but revenue rose 8,800% year over year to $8.86 million.
• Analyst sentiment remains broadly positive, with 14 Buy ratings, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $50.12.

Deutsche Bank AG bought a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 93,844 shares of the company's stock, valued at approximately $3,498,000. Deutsche Bank AG owned about 0.11% of IDEAYA Biosciences at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. GSK plc acquired a new stake in IDEAYA Biosciences in the 4th quarter worth approximately $46,093,000. State Street Corp raised its holdings in shares of IDEAYA Biosciences by 27.6% in the fourth quarter. State Street Corp now owns 4,134,641 shares of the company's stock worth $142,935,000 after buying an additional 893,707 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of IDEAYA Biosciences by 11.8% during the fourth quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company's stock worth $248,344,000 after buying an additional 758,117 shares during the period. First Turn Management LLC purchased a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at $25,017,000. Finally, Fiera Capital Corp grew its holdings in shares of IDEAYA Biosciences by 32.6% during the fourth quarter. Fiera Capital Corp now owns 2,437,262 shares of the company's stock valued at $84,256,000 after buying an additional 599,295 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $41.58 on Thursday. The stock has a market capitalization of $3.65 billion, a price-to-earnings ratio of -21.43 and a beta of -0.10. The firm's 50 day simple moving average is $36.78 and its 200-day simple moving average is $33.05. IDEAYA Biosciences, Inc. has a 12 month low of $23.23 and a 12 month high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.16). The firm had revenue of $8.86 million during the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The business's revenue for the quarter was up 8800.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.88) earnings per share. Analysts anticipate that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IDYA has been the topic of a number of research reports. Wedbush increased their price objective on IDEAYA Biosciences from $58.00 to $60.00 and gave the company an "outperform" rating in a report on Wednesday, August 5th. Wall Street Zen lowered shares of IDEAYA Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Citigroup reaffirmed a "market outperform" rating on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Mizuho decreased their target price on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada lowered their price target on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an "outperform" rating on the stock in a report on Tuesday, July 7th. Fourteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $50.12.

Insider Activity at IDEAYA Biosciences

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of the firm's stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total transaction of $382,095.50. Following the sale, the chief accounting officer directly owned 26,466 shares in the company, valued at $1,058,904.66. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.70% of the stock is owned by company insiders.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source